Published in Cancer on October 15, 1995
The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer (2004) 1.17
Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer (2006) 1.14
Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer (1999) 1.03
C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One (2015) 1.03
Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis (1998) 0.98
The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer (2006) 0.86
Prognostic factors in renal cell carcinoma. Urologe A (2004) 0.82
iTRAQ-Based Quantitative Proteomic Analysis Identified HSC71 as a Novel Serum Biomarker for Renal Cell Carcinoma. Biomed Res Int (2015) 0.75
Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur J Biochem (1980) 4.35
Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int (1999) 2.19
CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem J (1981) 1.91
Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int (2004) 1.79
Insect immunity. I. Characteristics of an inducible cell-free antibacterial reaction in hemolymph of Samia cynthia pupae. Infect Immun (1974) 1.78
Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol (2000) 1.68
Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol (1998) 1.47
Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol (2000) 1.35
Superoxide dismutase, catalase and scavengers of hydroxyl radical protect against the toxic action of alloxan on pancreatic islet cells in vitro. Biochem J (1979) 1.32
Superoxide dismutase is a prophylactic against alloxan diabetes. Nature (1981) 1.20
Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival. J Urol (1995) 1.17
p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer (2000) 1.14
Insect immunity. 11. Simultaneous induction of antibacterial activity and selection synthesis of some hemolymph proteins in diapausing pupae of Hyalophora cecropia and Samia cynthia. Infect Immun (1975) 1.13
Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker. Eur Urol (1992) 1.04
Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study. Ann Oncol (2011) 1.03
Fruits and vegetables consumption and the risk of histological subtypes of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control (2010) 1.02
Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev (2002) 1.00
Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? Br J Cancer (1999) 0.95
Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer (1997) 0.95
Plasma prealbumin in women with epithelial ovarian carcinoma. Gynecol Obstet Invest (1994) 0.92
Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase, and modified nucleosides as biological markers in malignant lymphomas. Recent Results Cancer Res (1983) 0.91
Alloxan cytotoxicity in vitro. Microscope photometric analyses of Trypan Blue uptake by pancreatic islet cells in suspension. Biochem J (1977) 0.89
The free beta-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. Br J Cancer (2002) 0.89
Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines. Br J Cancer (1988) 0.88
Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol (1999) 0.87
Induction of apoptosis by intracellular potassium ion depletion: using the fluorescent dye PBFI in a 96-well plate method in cultured lung cancer cells. Toxicol In Vitro (2006) 0.87
Influence of trace metals on alloxan cytotoxicity in pancreatic islets. FEBS Lett (1979) 0.86
Serum beta 2-microglobulin and prognosis of patients with renal cell carcinoma. Acta Oncol (1996) 0.85
Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol (2001) 0.85
Alloxan-induced luminol luminescence as a tool for investigating mechanisms of radical-mediated diabetogenicity. Biochem J (1981) 0.85
Identification of potassium flux pathways and their role in the cytotoxicity of estramustine in human malignant glioma, prostatic carcinoma and pulmonary carcinoma cell lines. Eur J Cancer (1994) 0.83
The effect of estramustine on microtubuli is different from the direct action via oxygen radicals on DNA and cell membrane. Anticancer Res (1990) 0.83
Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. Int J Cancer (1997) 0.83
Patient-centred care--preanalytical factors demand attention: a questionnaire study of venous blood sampling and specimen handling. Scand J Clin Lab Invest (2007) 0.83
Cisplatin-induced apoptosis of mesothelioma cells is affected by potassium ion flux modulator amphotericin B and bumetanide. Int J Cancer (2001) 0.82
Trypan Blue as a marker of plasma membrane permeability in alloxan-treated mouse islet cells. J Endocrinol Invest (1979) 0.82
Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance. Cell Death Dis (2010) 0.82
Neuroendocrine differentiation in renal cell carcinoma--evaluation of chromogranin A and neuron-specific enolase. Acta Oncol (1999) 0.82
Testosterone, SHBG and albumin in patients with ovarian carcinoma. Acta Obstet Gynecol Scand (1986) 0.81
Hormones in 'young' and 'old' elderly: pituitary-thyroid and pituitary-adrenal axes. Gerontology (1989) 0.81
Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer (2001) 0.81
Re: False-positive prostate specific antigen values in the sera of women with renal cell carcinoma. J Urol (1994) 0.81
Early morphological detection of estramustine cytotoxicity measured as alteration in cell size and shape by a new technique of microperifusion. Eur J Cancer (1991) 0.80
Serum dehydroepiandrosterone sulfate in Alzheimer's disease and in multi-infarct dementia. Biol Psychiatry (1991) 0.80
Estramustine binding protein in human brain-tumor tissue. J Neurosurg (1991) 0.80
Partial protection against streptozotocin-induced hyperglycaemia by superoxide dismutase linked to polyethylene glycol. Acta Endocrinol (Copenh) (1984) 0.79
Effects of estramustine on DNA and cell membrane in malignant glioma cells. Acta Oncol (1991) 0.79
Diverging effects of 5-HT3 receptor antagonists ondansetron and granisetron on estramustine-inhibited cellular potassium transport. Pharmacol Toxicol (2001) 0.79
Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells. Eur J Cancer (1999) 0.79
Selenite-induced increase in glutathione peroxidase activity protects human cells from hydrogen peroxide-induced DNA damage, but not from damage inflicted by ionizing radiation. Int J Radiat Biol (1989) 0.79
DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain--suggesting an apoptotic cell death. Br J Cancer (1995) 0.78
In vivo fluorescence microscopy of blood flow in mouse pancreatic islets: adrenergic effects in lean and obese-hyperglycemic mice. Microvasc Res (1985) 0.78
Relationship between CA 125 and progesterone production in women with ovarian carcinoma. Cancer (1990) 0.78
Response in shape and size of individual p31 cancer cells to cisplatin and ouabain: a computerized image analysis of cell halo characteristics during continuous perfusion. Cytometry (2000) 0.78
Human chorionic gonadotropin, follicle-stimulating hormone, and luteinizing hormone in patients with epithelial ovarian carcinoma. Gynecol Oncol (1990) 0.78
Increased serum cortisol levels are associated with high tumour grade in patients with renal cell carcinoma. Acta Oncol (2001) 0.78
Rubidium uptake by mouse pancreatic islets exposed to 6-hydroxydopamine, ninhydrin, or other generators of hydroxyl radicals. Acta Pharmacol Toxicol (Copenh) (1986) 0.78
Amphotericin B-induced apoptosis and cytotoxicity is prevented by the Na+, K+, 2Cl(-)-cotransport blocker bumetanide. Life Sci (2000) 0.77
Assessment of hypothalamic-pituitary function in patients with familial amyloidotic polyneuropathy. J Intern Med (1991) 0.77
Interactions between anticancer drugs and other clinically used pharmaceuticals. A review. Acta Oncol (1989) 0.77
Effects of clonidine-induced hypotension and dopamine-induced hypertension on blood flows in prostatic adenocarcinoma (Dunning R3327) and normal tissues. Prostate (1992) 0.77
Tumor markers in bronchogenic carcinoma. An evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase and pseudouridine. Acta Radiol Oncol (1983) 0.77
Growth hormone deficiency impairs blood clotting and reduces factor VII coagulant activity in rat. Thromb Haemost (1995) 0.76
Acetaminophen protection against estramustine-induced cytotoxicity on cultured fibroblasts. Pharmacol Toxicol (1998) 0.76
Perivascular cell protection in vivo and increased cell survival in vitro by the antihypertensive agent carvedilol following radiation. Eur J Cancer (1999) 0.76
Intra- and inter-laboratory reproducibility of estrogen and progesterone receptor enzyme immunoassay in breast cancer cytosol samples--a Swedish multicenter study. Swedish Society of Cancer Study Group. Acta Oncol (1997) 0.76
Glycoprotein tumour markers in head and neck neoplasms--a consecutive study on CA-50, CA 19-9, and CEA. J Cancer Res Clin Oncol (1988) 0.76
Thioredoxin and thioredoxin reductase in pancreatic islets may participate in diabetogenic free-radical production. Biochem Biophys Res Commun (1982) 0.76
Rapid induction of long-lasting drug efflux activity in brain vascular endothelial cells but not malignant glioma following irradiation. Med Oncol (2002) 0.76
Acquired neonatal thyroid disease due to TSH receptor antibodies in breast milk. J Pediatr Endocrinol Metab (2006) 0.76
Protective effect of iron chelators on epirubicin-induced fibroblast toxicity. Cancer Lett (1988) 0.76
Tumor markers in colorectal carcinoma. An evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase and pseudouridine. Acta Radiol Oncol (1984) 0.75
Computerized detection of morphological changes to glioma cells during estramustine and ion-channel blocker perifusion. Br J Cancer (1997) 0.75
Opposite effects of two metal-chelators on alloxan-induced diabetes in mice. Life Sci (1983) 0.75
Chlorpromazine enhancement of epirubicin cytotoxicity in vitro: effects on plasma membrane and DNA damage. Drug Metabol Drug Interact (1992) 0.75
Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma. Br J Cancer (1997) 0.75
[Interactions between cytostatic agents and other drugs]. Nord Med (1990) 0.75
Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro. Acta Oncol (1995) 0.75
Epirubicin cytotoxicity but not oxygen radical formation is enhanced by four different antiemetics. Med Oncol Tumor Pharmacother (1989) 0.75
Reduction of serum gonadotropin concentrations after parathyroidectomy. Acta Endocrinol (Copenh) (1989) 0.75
Assessment of thyroid and adrenal function in patients with familial amyloidotic polyneuropathy. J Intern Med (1989) 0.75
Misleading T3-test values in psychiatric patients treated with orphenadrine. Acta Med Scand (1987) 0.75
No effect of superoxide dismutase on spontaneous development of diabetes in db/db mice. Acta Endocrinol (Copenh) (1988) 0.75
Salivary cortisol during an overnight dexamethasone suppression test using a simple saliva collection device. Horm Metab Res (1990) 0.75
[The effect of diet on the treatment of malignant diseases]. Nord Med (1990) 0.75
[Salivary cortisol measurement--better than plasma assays]. Lakartidningen (1990) 0.75
Insulin-driven erythropoiesis may underlie impairment of erythrocyte deformability in hyperinsulinaemic, hyperglycaemic ob/ob-mice. Diabetologia (1990) 0.75
Effect of extracellularly generated free radicals on the plasma membrane permeability of isolated pancreatic B-cells. Int J Biochem (1986) 0.75
Diethyldithiocarbamate, but not disulfiram, inhibits alloxan-induced dye accumulation of isolated mouse islet beta-cells. Med Biol (1986) 0.75
Ultrastructure and membrane permeability of cultured pancreatic beta-cells exposed to alloxan or 6-hydroxydopamine. Virchows Arch A Pathol Anat Histopathol (1984) 0.75
Anti-Mullerian hormone and risk of invasive serous ovarian cancer. Cancer Causes Control (2014) 0.75
Placental and placental-like alkaline phosphatases in sera from healthy adults and cancer patients. Prog Clin Biol Res (1984) 0.75
Physical symptoms in premenstrual syndrome are related to plasma progesterone and desoxycorticosterone. Gynecol Endocrinol (2000) 0.75